EVERDIUM
DEAD

Serial Number

90669884

Owner

Bausch Health Ireland Limited

Attorney

Jeremy Blackowicz

Filing Date

Apr 25, 2021

Add to watchlist:

No watchlists yet
View on USPTO

EVERDIUM Trademark

Serial Number: 90669884

EVERDIUM is a trademark filed by Bausch Health Ireland Limited on April 25, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

Bausch Health Ireland Limited

3013 Lake Drive Citywest Business Campus

Entity Type: 99

Trademark Details

Filing Date

April 25, 2021

Registration Date

Not Registered

Published for Opposition

August 16, 2022

Goods & Services

Radio frequency medical devices for contracting skin, body sculpting, and soft tissue reconstruction in a non-invasive manner; Medical devices for aesthetic and therapeutic applications for the skin and its subcutaneous structures, namely, a device for delivering energy to the skin and its underlying tissues; Lasers and radio frequency devices for medical and aesthetic treatment; Medical devices, namely, medical instruments designed for the non-invasive removal of human body fat using an external energy source

Pharmaceutical preparations and substances for diagnosis and treatment of oral disease, namely, periodontitis, oral mucousitis and bone and soft tissue regeneration; Medicated pharmaceutical preparations and substances for the treatment and prevention of gastrointestinal diseases and disorders in humans including constipation, hepatic encephalopathy, irritable bowel syndrome, opioid-induced constipation and ulcerative colitis; Medicated beverages, powders, and gels for colonoscopies and endoscopic procedures; Pharmaceutical preparations and substances to prevent and treat diabetes mellitus, epilepsy, migraines, anxiety and depression, chronic pain, headaches, psychiatric disorders, and rare diseases such as Wilson and Huntington's disease, diabetes mellitus, cardiovascular/angina, hyperammonaemia, hormone deficiencies (endocrinology), cancer, otolaryngology, and urinary tract, lungs, heart infections and diseases, central nervous system disorders, neuromuscular conditions, vaginal disorders; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations and substances for the treatment of skin and nail conditions, namely, acne, psoriasis, onychomycosis, tinea pedis, actinic keratosis, rosacea and other dermatoses, fungal infections; Vitamins and mineral supplements

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 11, 2026 ASCK
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 14, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 14, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 26, 2025 EXRA
SOU EXTENSION 5 GRANTED
Jul 25, 2025 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 25, 2025 AITU
SOU EXTENSION 5 FILED
Apr 11, 2025 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 11, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 2, 2024 EX4G
SOU EXTENSION 4 FILED
Oct 2, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 2, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 2, 2024 EXRA
SOU EXTENSION 3 GRANTED
Apr 1, 2024 EX3G
SOU EXTENSION 3 FILED
Apr 1, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 1, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 11, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 9, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 9, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 9, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 5, 2023 EXRA
SOU EXTENSION 1 GRANTED
Apr 3, 2023 EX1G
SOU EXTENSION 1 FILED
Apr 3, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 3, 2023 EEXT
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 8, 2023 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jan 18, 2023 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 28, 2022 ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Dec 14, 2022 ASCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 11, 2022 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 22, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 22, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 22, 2022 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 12, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 7, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 7, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 7, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 7, 2022 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 1, 2021 GNRN
NON-FINAL ACTION E-MAILED
Dec 1, 2021 GNRT
NON-FINAL ACTION WRITTEN
Dec 1, 2021 CNRT
ASSIGNED TO EXAMINER
Dec 1, 2021 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 16, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 16, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 16, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 16, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 16, 2021 COAR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 30, 2021 NWOS
NEW APPLICATION ENTERED
Apr 28, 2021 NWAP